Finding aggressive
prostate cancer earlier
Our approach
Prostate cancer is the most common cancer in men globally. Early detection is key to successful treatment.
90 000+
Participants in clinical studies [1]
41-89%
More aggressive cancers found [2]
37-52%
Fewer unnecessary biopsies [3]
8-28%
Lower healthcare costs [4]
Press releases
Stockholm3 included in NCCN guidelines for Prostate Cancer Early Detection
A3P Biomedical appoints Christopher O’Connell as Board Director
Stockholm3 outperforms other prostate cancer biomarkers and risk calculators
Stockholm3 validated in repeat screening for prostate cancer
Stockholm3 launched in Germany
Strategic partnership for Stockholm3 in Switzerland
All Press releases